Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.37 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.34 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.34 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27340963 | 0.98 | CYP2C9 (0.50) | TDP1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL876467 | 0.98 | CYP2C9 (0.50) | TDP1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL12174842 | 0.82 | CYP2C9 (0.50) | TDP1CYP2C9TSHRCYP2C19MTOR | |
| Hydrochloric Acid SCHEMBL1310275 | 0.81 | TDP1 (0.58) | TDP1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL7842865 | 0.81 | CYP2C9 (0.48) | TDP1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL2176873 | 0.81 | CYP2C9 (0.53) | TDP1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL25226943 | 0.80 | CYP2C9 (0.39) | TDP1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL14665172 | 0.79 | CYP2C9 (0.47) | TDP1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL2629331 | 0.79 | CYP2C9 (0.56) | TDP1CYP2C9TSHRCYP2C19MTOR | |
| SCHEMBL12158515 | 0.78 | CYP2C9 (0.46) | TDP1CYP2C9TSHRCYP2C19MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290779-B1 | Transfection compositions using amphipathic compounds | MIRUS BIO LLC | 2016-03-22 | — | — | US | disclosed |
| US-9051315-B2 | Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2496574-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | Abbott Laboratories (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110124632-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2011053476-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20090170749-A1 | Novel Compounds Which Interact With PEA-15 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-07-02 | — | — | US | disclosed |
| CN-101336248-A | Novel compounds which interact with PEA-15 | INST NAT SANTE RECH MED (FR) | 2008-12-31 | — | — | CN | disclosed |
| EP-1960420-A2 | NOVEL COMPOUNDS WHICH INTERACT WITH PEA-15 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-08-27 | — | — | EP | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
| EP-0533244-B1 | Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists | MERCK & CO INC (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0532178-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| CN-1112117-A | Imidazole-containing inhibitors of farnesyl protein transferase | BRISTOL MYERS SQUIBB CO (US) | 1995-11-22 | — | — | CN | disclosed |
| EP-0675112-A1 | Imidazole-containing inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5455246-A | Treating neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1995-10-03 | — | — | US | disclosed |
| US-5266570-A | Neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-30 | — | — | US | disclosed |
| US-5204349-A | Treatment of preterm labor, dysmenorrhea and for stoppage of labor prior to cesarian delivery | MERCK & CO., INC. (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0533244-A1 | Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0532178-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | HRH3 2083/4885S1PR1 4523/4885GABRA5 3543/4885 |
| US-20090170749-A1 | Novel Compounds Which Interact With PEA-15 | PEBP1, EPS15, PSTPIP2 | HRH3 1546/4885S1PR1 3809/4885GABRA5 4195/4885 |
| US-20110124632-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | PACSIN2, MAP4K2, MAP3K6 | HRH3 2835/4885S1PR1 3473/4885GABRA5 3067/4885 |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | HRH3 548/4885S1PR1 1/4885GABRA5 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.